ArticleApplied biochemistry and biotechnology2026
Menstrual Blood Stem Cell-Derived Exosomes as Modulators of Apoptosis, Migration and Angiogenesis in Breast Cancer Cells.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The complexity of breast cancer cells complicates the process of enhancing our understanding, which may lead to the development of effective therapeutic agents and approaches. Among the novel medical interventions, menstrual blood-derived mesenchymal stem cells (Mens-MSCs) demonstrate proactive and immunomodulatory interactions with malignant cells. This study aims to evaluate the effects of Mens-MSCs-derived exosomes (MM-Exos) on breast cancer cell behaviors, with particular emphasis on apoptosis, migration, and angiogenesis. MM-Exos were characterized using DLS, flow cytometry, and TEM. After determining the effective concentration by MTT assay, the exosomes were applied to MDA-MB-231 and SK-BR-3 cell lines. Cell motility was evaluated using a scratch assay, while apoptosis, cell cycle distribution, and ROS generation were assessed by flow cytometry and ELISA. Gene expression of BAX, BCL-2, MMP-2, and VEGF was analyzed by qPCR, and corresponding protein levels were confirmed through Western blotting. Based on the results, MM-Exos dose-dependently decreased breast cancer cell survival across both cell lines. Furthermore, MM-Exos at 50 and 100 µg/ml significantly reduced the migratory rate of cell lines (P < 0.001). Treatment with MM-Exos (100 µg/ml) significantly increased ROS production (P < 0.001), enhanced apoptosis (P < 0.001), induced cell cycle arrest (P < 0.001), and altered gene and protein expression. Both cell lines exhibited significant down-regulation of VEGF(P < 0.001), BCL-2 (P < 0.01), and MMP-2 (P < 0.01) after treatment with MM-Exos, whereas BAX demonstrated significant up-regulation (P < 0.001). Based on results, MM-Exo demonstrates anticancer functions by enhancing cytotoxicity, ROS generation, apoptosis, while reducing migration rate. Thus, MM-Exo may represent a potential therapeutic option for breast cancer; however, further comprehensive studies are required.
Indexed as
Identifiers
42159846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.